<DOC>
	<DOC>NCT00825721</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract</brief_summary>
	<brief_title>Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Presence of nuclear sclerosis cataract BCDVA within the range of 20/40 and 20/80 Any other clinical condition in the eye that may compromise vision Presence or history of glaucoma Presence or history of diabetes Use of eyedrops Use of steroids</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Cataract Study</keyword>
	<keyword>Ophthalmic Study</keyword>
	<keyword>Agerelated cataract</keyword>
	<keyword>Nuclear Cataract</keyword>
	<keyword>Low grade nuclear cataracts</keyword>
</DOC>